315 related articles for article (PubMed ID: 33007739)
1. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
Prandoni P; Cattelan AM; Carrozzi L; Leone L; Filippi L; De Gaudenzi E; Villalta S; Pesavento R;
Thromb Res; 2020 Dec; 196():395-397. PubMed ID: 33007739
[No Abstract] [Full Text] [Related]
2. COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy.
Daughety MM; Morgan A; Frost E; Kao C; Hwang J; Tobin R; Patel B; Fuller M; Welsby I; Ortel TL
Thromb Res; 2020 Dec; 196():483-485. PubMed ID: 33091700
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Russo V; Cardillo G; Viggiano GV; Mangiacapra S; Cavalli A; Fontanella A; Agrusta F; Bellizzi A; Amitrano M; Iannuzzo M; Sacco C; Lodigiani C; Di Micco P
J Cardiovasc Pharmacol; 2020 Oct; 76(4):369-371. PubMed ID: 33027192
[TBL] [Abstract][Full Text] [Related]
4. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
Kreidieh F; Temraz S
Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy.
Gibson CM; Korjian S; Chi G; Daaboul Y; Jain P; Arbetter D; Goldhaber SZ; Hull R; Hernandez AF; Lopes RD; Gold A; Cohen AT; Harrington RA;
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28698258
[TBL] [Abstract][Full Text] [Related]
7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
8. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection.
Trunfio M; Salvador E; Cabodi D; Marinaro L; Alcantarini C; Gaviraghi A; Trentalange A; Lipani F; Sciascia S; Roccatello D; Bonora S; Di Perri G; Calcagno A;
Thromb Res; 2020 Dec; 196():432-434. PubMed ID: 33049598
[No Abstract] [Full Text] [Related]
9. Comparison of the Effects of Low-Molecular-Weight Heparin and Fondaparinux on Liver Function in Patients With Pulmonary Embolism.
Yang X; Li N; Guo T; Guan X; Tan J; Gao X; Wu Y; Jia L; Gu M; Hua L; Liu H
J Clin Pharmacol; 2020 Dec; 60(12):1671-1678. PubMed ID: 32639644
[TBL] [Abstract][Full Text] [Related]
10. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience.
Pesavento R; Ceccato D; Pasquetto G; Monticelli J; Leone L; Frigo A; Gorgi D; Postal A; Marchese GM; Cipriani A; Saller A; Sarais C; Criveller P; Gemelli M; Capone F; Fioretto P; Pagano C; Rossato M; Avogaro A; Simioni P; Prandoni P; Vettor R
J Thromb Haemost; 2020 Oct; 18(10):2629-2635. PubMed ID: 32692874
[TBL] [Abstract][Full Text] [Related]
11. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
[No Abstract] [Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Cafri G; Paxton EW; Chen Y; Cheetham CT; Gould MK; Sluggett J; Bini SA; Khatod M
J Arthroplasty; 2017 Nov; 32(11):3524-3528.e1. PubMed ID: 28634095
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
15. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin.
Yoshida Rde A; Yoshida WB; Maffei FH; El Dib R; Nunes R; Rollo HA
Ann Vasc Surg; 2013 Apr; 27(3):355-69. PubMed ID: 23351997
[TBL] [Abstract][Full Text] [Related]
16. Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity.
Garner MP; Onuoha CP; Fenn NE
Ann Pharmacother; 2021 May; 55(5):666-676. PubMed ID: 32864984
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux Sodium Compared With Low-Molecular-Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta-analysis.
Kumar A; Talwar A; Farley JF; Muzumdar J; Schommer JC; Balkrishnan R; Wu W
J Am Heart Assoc; 2019 May; 8(10):e012184. PubMed ID: 31070069
[TBL] [Abstract][Full Text] [Related]
18. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
[TBL] [Abstract][Full Text] [Related]
19. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
Tang Y; Wang K; Shi Z; Yang P; Dang X
Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
[TBL] [Abstract][Full Text] [Related]
20. Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Sharifova G; Cohen M; Lund JM; Mignatti A; Gianos E; Tafur A; Lewis PA; Cohoon K; Kittelson JM; Lesser ML; Sison CP; Rahman H; Ochani K; Hiatt WR; Dale RA; Anderson VE; Bonaca M; Halperin JL; Weitz JI; Spyropoulos AC
Thromb Haemost; 2021 Dec; 121(12):1684-1695. PubMed ID: 33823560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
